The physiology of the gastric parietal cell
AC Engevik, I Kaji, JR Goldenring - Physiological reviews, 2020 - journals.physiology.org
Parietal cells are responsible for gastric acid secretion, which aids in the digestion of food,
absorption of minerals, and control of harmful bacteria. However, a fine balance of activators …
absorption of minerals, and control of harmful bacteria. However, a fine balance of activators …
Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics
CA Fallone, SF Moss, P Malfertheiner - Gastroenterology, 2019 - Elsevier
Increasing resistance to antibiotics worldwide has adverse effects on the effectiveness of
standard therapies to eradicate Helicobacter pylori infection. We reviewed guidelines …
standard therapies to eradicate Helicobacter pylori infection. We reviewed guidelines …
Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in …
J Hu, H Mei, N Su, W Sun, D Zhang, L Fan, P He… - …, 2023 - Wiley Online Library
Background Potassium‐competitive acid blockers (P‐CAB) are recommended for the
treatment of Helicobacter pylori infections, but dual therapy of P‐CAB with amoxicillin has …
treatment of Helicobacter pylori infections, but dual therapy of P‐CAB with amoxicillin has …
Review – Treatment of Helicobacter pylori infection 2020
This review summarizes important studies regarding Helicobacter pylori therapy published
from April 2019 to April 2020. The main themes that emerge involve studies assessing …
from April 2019 to April 2020. The main themes that emerge involve studies assessing …
[HTML][HTML] Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases
T Oshima, H Miwa - Journal of neurogastroenterology and motility, 2018 - ncbi.nlm.nih.gov
Conventional proton pump inhibitors (PPIs) are used as a first-line therapy to treat acid-
related diseases worldwide. However, they have a number of limitations including slow …
related diseases worldwide. However, they have a number of limitations including slow …
Recent progress in Helicobacter pylori treatment
Y Hu, Y Zhu, NH Lu - Chinese Medical Journal, 2020 - mednexus.org
The main challenge in the field of Helicobacter pylori (H. pylori) infection is antibiotic
resistance, which influences the efficacy of eradication regimens. Bismuth-containing …
resistance, which influences the efficacy of eradication regimens. Bismuth-containing …
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study
Background Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve
acceptable cure rates for treatment of Helicobacter pylori (H. pylori) in Japan. Its …
acceptable cure rates for treatment of Helicobacter pylori (H. pylori) in Japan. Its …
A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta …
DM Simadibrata, AF Syam… - … of Gastroenterology and …, 2022 - Wiley Online Library
Abstract Background and Aim Potassium‐competitive acid blocker (PCAB) is a recent
alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic …
alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic …
Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis
RC Du, YX Hu, Y Ouyang, LX Ling, JY Xu, R Sa… - …, 2024 - Wiley Online Library
Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin
(VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different …
(VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different …